English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

Nottingham University, UK

Bookmark and Share

ESMO 33

12 - 16 Sep 2008

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues

Published: 3 Dec 2008
Views: 17561
Rating:
Save
Prof. Poulam Patel
Extended, escalated dose chemo shows no survival benefit in advanced melanoma.
  • Categories:
  • Melanoma & skin

Related Videos

Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
14 Sep 2022
Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...
Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands
Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2022
Tumour-infiltrating lymphocyte treatment for advanced melanoma
Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands
Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2022
Pembrolizumab demonstrates clinically meaningful improvement in distant...
Dr Georgina Long - The University of Sydney, Sydney, Australia
Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )
6 Jun 2022
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...
Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands
Neoadjuvant ipilimumab and nivolumab  immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2023 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top